- Home
- PHAT vs BCSF Comparison
PHAT vs BCSF Comparison
Compare PHAT & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | BCSF |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.6M | 901.0M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PHAT | BCSF |
|---|---|---|
| Price | $17.56 | $13.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $17.33 | $15.50 |
| AVG Volume (30 Days) | ★ 870.6K | 381.8K |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 12.92% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.44 |
| Revenue | $147,190,000.00 | ★ $278,347,000.00 |
| Revenue This Year | $220.37 | N/A |
| Revenue Next Year | $83.14 | N/A |
| P/E Ratio | ★ N/A | $9.69 |
| Revenue Growth | ★ 460.30 | N/A |
| 52 Week Low | $2.21 | $13.20 |
| 52 Week High | $18.31 | $19.21 |
Technical Indicators
Market Signals| Indicator | PHAT | BCSF |
|---|---|---|
| Relative Strength Index (RSI) | 66.74 | 45.90 |
| Support Level | $16.77 | $13.68 |
| Resistance Level | $18.31 | $14.24 |
| Average True Range (ATR) | 0.88 | 0.23 |
| MACD | 0.26 | -0.06 |
| Stochastic Oscillator | 79.95 | 26.67 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.